Table of Contents Author Guidelines Submit a Manuscript
International Journal of Biomedical Imaging
Volume 2011 (2011), Article ID 370701, 8 pages
Review Article

Molecular Imaging in Tumor Angiogenesis and Relevant Drug Research

Intelligent Medical Research Center, Institute of Automation, Chinese Academy of Sciences, Beijing 100190, China

Received 9 March 2011; Revised 16 May 2011; Accepted 23 May 2011

Academic Editor: Habib Zaidi

Copyright © 2011 Xibo Ma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Molecular imaging, including fluorescence imaging (FMI), bioluminescence imaging (BLI), positron emission tomography (PET), single-photon emission-computed tomography (SPECT), and computed tomography (CT), has a pivotal role in the process of tumor and relevant drug research. CT, especially Micro-CT, can provide the anatomic information for a region of interest (ROI); PET and SPECT can provide functional information for the ROI. BLI and FMI can provide optical information for an ROI. Tumor angiogenesis and relevant drug development is a lengthy, high-risk, and costly process, in which a novel drug needs about 10–15 years of testing to obtain Federal Drug Association (FDA) approval. Molecular imaging can enhance the development process by understanding the tumor mechanisms and drug activity. In this paper, we focus on tumor angiogenesis, and we review the characteristics of molecular imaging modalities and their applications in tumor angiogenesis and relevant drug research.